Head-To-Head Survey: Eyenovia (NASDAQ:EYEN) versus Indivior (OTCMKTS:INVVY)

Indivior (OTCMKTS:INVVYGet Rating) and Eyenovia (NASDAQ:EYENGet Rating) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.

Volatility & Risk

Indivior has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, Eyenovia has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.

Profitability

This table compares Indivior and Eyenovia’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Indivior 18.04% 66.83% 7.91%
Eyenovia N/A -80.28% -54.46%

Earnings and Valuation

This table compares Indivior and Eyenovia’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Indivior $791.00 million 4.23 $205.00 million $1.05 23.33
Eyenovia $14.00 million 5.65 -$12.78 million ($0.57) -3.84

Indivior has higher revenue and earnings than Eyenovia. Eyenovia is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Indivior and Eyenovia, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indivior 0 0 1 0 3.00
Eyenovia 0 0 1 0 3.00

Eyenovia has a consensus target price of $12.00, suggesting a potential upside of 447.95%. Given Eyenovia’s higher possible upside, analysts plainly believe Eyenovia is more favorable than Indivior.

Insider & Institutional Ownership

0.1% of Indivior shares are owned by institutional investors. Comparatively, 6.2% of Eyenovia shares are owned by institutional investors. 9.7% of Eyenovia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Indivior beats Eyenovia on 7 of the 12 factors compared between the two stocks.

About Indivior

(Get Rating)

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

About Eyenovia

(Get Rating)

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.